Sexual Dysfunction after Pelvic Surgery

Early Penile Rehabilitation

Introduction

The introduction of prostate screening programs, which include annual digital rectal examinations and PSAs, has led to earlier detection of most prostate malignancies. Earlier detection has significantly improved cancer cure, allowing us to redirect our focus towards quality of life issues. It has become apparent that erectile function is a significant problem following RP. Currently, potency rates range between 30 and 60% in the reported literature. Potency rates from the experienced surgeons would indicate that, even after a considerable volume of experience, ED following nerve injury is a major problem.

Urologists have been the pioneers in recognizing the impact of radical pelvic surgery on sexual dysfunction. Multiple authors have reported their techniques on nerve-sparing RP from the retropubic, perineal or laparoscopic approach. These reports have provided the stimulus for the other surgical fields to perform the nerve-sparing technique. In the world of colorectal surgeries, exciting new techniques for the treatment of rectal cancer has evolved like autonomic nerve preservation with TME. The concept of sexual dysfunction is evolving in the field of radical and as well as simple hysterectomies also. More urologists performing transvaginal sling procedures are recognizing female sexual dysfunction as an important issue. The concept of nerve-sparing surgery will soon be followed in radical and simple hysterectomy as well. These other disciplines will soon discover what urologists have learned, that despite anatomical nerve sparing there is still dysfunction due to the period of neuropraxia.

When analyzing potency rates following RP, it would appear that our focus should be into the rehabilitation and nerve recovery rather than looking for the further advances in the surgical technique. Urologists have led the way into early rehabilitation programs to promote the nerve recovery and nerve regeneration. These programs will soon evolve into other disciplines that are performing pelvic surgeries. Performing anatomical nerve-sparing procedures rarely guarantees immediate postoperative recovery of potency. So the other disciplines will soon develop early rehabilitation programs. We will discuss our experience with various early programs intended to shorten the period of neuropraxia after RP.Role of Oral Medications in Early Penile Rehabilitation

There is a growing interest among urologists regarding the early use of daily oral sildenafil. This was first reported by Padma-Nathan et al.,[95] who conducted a randomized controlled study in 76 men (oral sildenafil daily (50 mg, n=23; 100 mg, n=28), placebo=25) who underwent nerve-sparing RP with normal preoperative erectile function. Sildenafil was given for 36 weeks in the study group. After 48 weeks (~11 months) follow-up, 14 of 51 (27%) patients receiving sildenafil demonstrated return of spontaneous erections compared to one of 25 (4%) in the placebo group. This study revealed that oral daily sildenafil increased the return of erections to seven-folds compared with placebo group and was well tolerated. However, this study has been criticized because the return of spontaneous erections in the placebo group was only 4%, which is very low compared to the other reported series in the literature. Further multicenter randomized studies are ongoing to investigate the potential benefit of daily sildenafil following radical RP.Early MUSE

We recently completed a prospective nonrandomized study on the use of early MUSE after RP at the Cleveland Clinic Foundation. To our knowledge, this is the only report in literature. We included a total of 91 patients. Of the 91 patients, 56 received early MUSE and 35 (Control group) did not receive any early treatment. Patients in the early MUSE group received 125 µg 3 times/week for the first 6 weeks. At 6 weeks, the MUSE dose was titrated to 250 µg, 3 times/week for 4 months. Patients who could not tolerate the 250 µg doses remained at 125 µg for 4 months. Treatment efficacy was analyzed by the patient's response to the Sexual Health Inventory of Men (SHIM) questionnaire. In the MUSE Group, 38/56 (68%) continued MUSE treatment. At 6 months, 28/38 (74%) of the patients resumed sexual activity, 15/28 (53%) had natural erections sufficient for vaginal penetration without MUSE and 13/28 (47%) continue to use MUSE as an adjuvant treatment for successful intercourse. Overall, including those who discontinued MUSE, at 6 months 27% (15/56) achieved natural erections sufficient for sexual intercourse. The MUSE discontinuation rate was 32% (18/56). Nine of the 18 (50%) discontinued because of inadequate erections, five (28%) due to loss of sexual interest and four (22%) due to local pain/burning. In the Control Group, 13/35 (37%) resumed sexual activity, 4/13 (30.7%) had natural erections sufficient for vaginal penetration, 9/13 (69.3%) were dissatisfied with the erections and used oral therapy/erectaids as adjuvant treatments. Overall, in the control group 11% (4/35) at 6 months achieved natural erections sufficient for satisfactory sexual intercourse.

In our experience, early MUSE therapy following RP increased the frequency of sexual activity, increased the incidence of spontaneous erections sufficient for intercourse and appeared to shorten the neuropraxia period.Early VCD

We recently completed a prospective nonrandomized study on the use of early VCD after RP at the Cleveland Clinic, which included 109 patients who underwent RP between August 1999 and October 2001.[96] Of the 109 patients, 74 (Group 1) patients used early VCD daily for 9 months and 35 observed without any erectogenic treatment (Group 2). Treatment efficacy was analyzed by responses to the SHIM. Patient outcome regarding the compliance changes in the penile length and circumference, return of natural erection and ability for vaginal intercourse was also assessed. After a minimum follow-up of 9 months, 80% (60/74) in Group 1 successfully used their VCD with a constriction ring for vaginal intercourse at a frequency of twice per week, with an overall spousal satisfaction rate of 55% (33/60). Of these 60 patients, 19 (32%) reported return of natural erections at 9 months, with 10/19 (52%) having erections sufficient for sexual intercourse. The abridged IIEF-5 score significantly increased after VCD use in both the NS and NNS groups. After a mean use of 3 months, 14/74 (18%) discontinued treatment. Overall, in the early VCD group, 14% (10/74) had natural erections sufficient for sexual intercourse.

In Group 2, 37% (13/35) of patients regained spontaneous erections at a minimum follow-up of 9 months after surgery. However, only four of these patients (29%) had erections sufficient for successful vaginal intercourse and the rest of the patients (71%) sought adjuvant treatment. Overall, in the control group at 9 months, 11% (4/35) achieved natural erections sufficient for satisfactory sexual intercourse. Note that 11% vaginal intercourse rates were identical in both the Group 1 and 2.

Interestingly, when assessing the penile length and girth after surgery, of the 60 compliant patients, only 14 (23%) reported a decrease in penile length and girth at 9 months (range, 4-11 months), with 12/14 (85%) noncompliant patients complaining of decrease in penile length and girth. In the control group, 22/35 (63%) reported decrease in penile length and circumference, demonstrating that routine early use of the VCD helps in preventing the decrease in penile length and circumference.

We concluded that early use of VCD following RP facilitates early sexual intercourse, early patient/spousal sexual satisfaction, potentially an earlier return of natural erections sufficient for vaginal penetration and preservation of penile length and girth.Early Injections

Montorsi et al.[97] from Milan, Italy, first reported their experience using intracavernous injections in 1997. Of the total 30 patients who underwent nerve-sparing RP, 15 were randomized into Group 1 (alprostadil injections 3 times/week for 12 weeks) and another 15 patients were randomized into Group 2 (observation without erectaids). The dose of PGE1 varies from 4 to 14 µg, with a mean dose of 8 µg. At 6 months, 67% of the patients in the injection group reported to have return of spontaneous erections sufficient for satisfactory intercourse compared to 20% in the observation group. We initiated a similar study in 2001 with a dose of 10 µg PGE1 at the Cleveland Clinic Foundation. Of the eight patients, six discontinued because of pain, which prompted us to discontinue our early PGE1 program 3 years ago.

Recently, we wanted to re-examine the role of early intracorporeal injections, with lower dose of PGE1 (4 µg/2-3 times/week) starting at 2 weeks after RP, combined with oral sildenafil (50 mg/day). We reduced the injection dose to 4 µg, to get partial erections with minimal, if any, pain. Our goal was to have a compliance of more than 90%. Further modifications have been made according to the tolerance of patient and response; the dose of PGE1 was reduced to 2 µg in some patients with the same response to minimize the adverse effects and maximize the compliance. We included a total of 18 patients in this study. Of the total 18 patients, 16 were using injections with Viagra and two were using daily sildenafil alone. Of the total 16 patients, two increased the dose up to 8 µg without any pain (one having mild discomfort), six patients continuing the same dose of 4 µg and the rest of the patients decreased the dose. Of the eight patients who decreased the dose, six are using 2 µg dose and two patients further reduced the dose to 1 µg. Patients who were not willing for the injections given daily 50 mg oral sildenafil alone. Two patients were started only on Viagra. We are currently investigating the role of injections and oral sildenafil in patients who underwent nerve-sparing RC also. We included two patients in the study. Until now, the compliance with this program is 100%. After a mean follow-up of 10 weeks (4-18 weeks), 15/16 patients were sexually active. One patient sexually inactive due to incontinence. Our early data revealed that lower doses of IC PGE1 (4, 2 and 1 µg) with sildenafil was as effective as high doses of PGE1 alone (8 µg), without any penile discomfort ( Table 4 ). The reasons for these high compliance rates are good counseling and follow-up by the physician and proper dose modification according to the patient's desire and side effects. Early injection facilitated early sexual intercourse, patient and spousal satisfaction.   Printer- Friendly Email This

Int J Impot Res.  2006;18(1):1-18.  ©2006 Nature Publishing Group
This is a part of article Sexual Dysfunction after Pelvic Surgery Taken from "Male Erectile Disfunction" Information Blog

BBC NEWS | Special Report | 1998 | Viagra | Viagra impotence warning

Thursday, 28 January, 1999, 17:26 GMT Viagra impotence warning
Viagra has disturbing side effects
Young men who take Viagra for recreational use risk impotence, an expert has warned.

The hype surrounding the drug has lead to some using it in nightclubs as an aphrodisiac.

Roger Kirby, a consultant urologist from St George's Hospital in London, says young men are already reported to be experiencing medical problems after taking Viagra (technical name sildenafil).

They have developed a persistent and painful erection, a condition known as priapism.

This condition may result in a lack of blood supply to and consequent damage of the intracavernosal smooth muscle, the muscle that helps to produce an erection.

Drugs cocktail

The damage may cause the sufferer to develop permanent impotence problems (erectile dysfunction).

Mr Kirby, honorary secretary of the British Association of Urological Surgeons, says there is no data to support the claim that Viagra improves the normal erection or alters orgasmic sensation.

Writing in the Student British Medical Journal, he also issues a warning to men considering taking Viagra as part of a drugs cocktail.

If it is taken with any drug containing nitric oxide (such as "poppers", which contain amyl nitrate) it could be extremely hazardous.

This is because the potentially lethal combination can lead to a decline in blood pressure that could cause a heart attack or stroke.

Side effects

According to Mr Kirby, the other side effects of any man taking Viagra, whether impotent or not, are headaches, facial flushing and heartburn.

The effect of the drug on the retina may also result in temporary abnormalities of vision and the perception of a "blue haze".

In conclusion, Mr Kirby said: "Sildenafil has little to offer normally potent men and usage by them carries inherent risks.

"The message is don't take it if you have not got erectile dysfunction. It is not a good recreational drug."

However, Mr Kirby stressed that Viagra has proved to be a "breakthrough drug" for the treatment of erectile dysfunction.

He criticised the decision of Health Secretary Frank Dobson to limit the availability of the drug on the NHS.

Guidelines 'unworkable'

Impotence is not a life-threatening condition in its own right, Mr Kirby argues, but it is associated with a serious reduction in the quality of life, not only for the men affected but also for their partners.

"The men lose confidence and often become depressed," he writes. "Their partners feel rejected and often misinterpret the lack of sexual relations as a sign of transference of affections elsewhere."

Mr Kirby told BBC News Online that patients had already complained to him since Mr Dobson announced new guidelines for the NHS prescription of the drug last week.

" A lot of people are very disappointed, they feel it goes against the ethics of the NHS, and that if they have medical condition it should be treated," he said.

"The guidelines are unworkable. They divide people with erectile dysfunction into those who deserve treatment and those who do not on a very arbitrary basis."

WATCH/LISTEN  ON THIS STORY Audio Roger Kirby: "Taking Viagra recreationally is not a good idea" Video The BBC's Toby Sealey: "Recreational use could cause lasting damage" Audio r See also: 21 Jan 99 | HealthViagra linked to five UK deaths 12 Mar 99 | ViagraViagra risks unproven 12 Mar 99 | HealthViagra: The rationing precedent Internet links: Erectile dysfunctionBritish Medical JournalImpotence The BBC is not responsible for the content of external internet sites Top Viagra stories now: Viagra 'limited to cut cost' Viagra action 'legally indefensible' More men to get NHS Viagra Keep on prescribing Viagra, doctors told Women can benefit from Viagra NHS bosses: Restrict Viagra 'Give impotent men Viagra' Clubbers taking Viagra cocktail Links to more Viagra stories are at the foot of the page.

	E-mail this story to a friend

Links to more Viagra stories In This SectionViagra 'limited to cut cost'Viagra action 'legally indefensible'More men to get NHS ViagraKeep on prescribing Viagra, doctors toldWomen can benefit from ViagraNHS bosses: Restrict Viagra'Give impotent men Viagra'Clubbers taking Viagra cocktail'Stop Viagra mail shots'Viagra impotence warningViagra patients could sue, says doctorDoctors rebel against 'cruel' Viagra rulesViagra risks unprovenViagra: The rationing precedentFast-acting Viagra spray developedGPs issue 10-day deadline on ViagraViagra attracts £338m in six monthsDogs mutilated in Viagra testViagra ban backed by GPsDoctors: Why we oppose Viagra rationing

		^^ Back to top News Front Page | World | UK | England | N Ireland | Scotland | Wales | UK Politics | Business | Entertainment | Science/Nature | Technology | Health | Education | Talking Point | Country Profiles | In Depth | Programmes

———————————————————————————- To BBC Sport>> | To BBC Weather>> | To BBC World Service>> ———————————————————————————- © MMIII | News Sources | Privacy var si = document.location+""; var tsi = si.replace(".stm","").substr(si.length-11, si.length); if (!tsi.match(/\d\d\d\d\d\d\d/)) {tsi = 0;} document.write('<img src="http://stats.bbc.co.uk/o.gif?~RS~s~RS~News~RS~t~RS~HighWeb_Legacy~RS~i~RS~' + tsi + '~RS~p~RS~0~RS~u~RS~/2/hi/special_report/1998/viagra/263971.stm~RS~r~RS~(none)~RS~a~RS~Domestic~RS~q~RS~~RS~z~RS~07~RS~">');

This is a part of article BBC NEWS | Special Report | 1998 | Viagra | Viagra impotence warning Taken from "Male Erectile Disfunction" Information Blog

Cost Studies in Rheumatology, 2001-2002

Cost Studies in Rheumatology, 2001-2002

from Current Opinion in Rheumatology

Management of Infected Total Joint Replacement

Fisman et al.[9] performed an excellent study examining the cost-effectiveness of two-stage exchange arthroplasty and open debridement with prosthesis retention in elderly patients with infected total hip arthroplasty. Lifetime direct medical costs as well as indirect costs from loss of productivity were assessed using a Markov model. Incremental ratios demonstrated that when compared with exchange arthroplasty, initial debridement and retention had lower cost-effectiveness ratios ($500-$21,800/QALY) in all cohorts regardless of gender.

This is a part of article Cost Studies in Rheumatology, 2001-2002 Taken from "Leflunomide Arava 20Mg" Information Blog

Gastro-oesophageal Reflux During Pregnancy: Treat With Care

Gastro-oesophageal Reflux During Pregnancy: Treat With Care

from Drugs & Therapy Perspectives

Can Occur at Any Time

Typically, gastro-oesophageal reflux in pregnancy is of new onset. For those patients with pre-existing gastro-oesophageal reflux, symptoms may continue or worsen during gestation.

Gastro-oesophageal reflux can occur at any time during pregnancy and symptoms usually resolve post partum.[1]

Symptoms Similar to the General PopulationSymptoms of gastro-oesophageal reflux are no different during pregnancy than at any other time. The predominant symptoms are heartburn and regurgitation.[1] Other common complaints include indigestion, epigastric pain, waterbrash, anorexia, nausea and vomiting.

Precipitating factors include eating before bedtime, ingestion of fatty or spicy foods, caffeinated beverages, mints or chocolates, and sometimes inadvertent use of drugs that decrease lower oesophageal sphincter pressure (e.g. calcium antagonists, anticholinergics). Complications (e.g. oesophagitis) are rare in pregnancy.

Hormones Play a RoleAlthough the exact mechanism is unknown, the pathophysiology of gastro-oesophageal reflux in pregnancy is probably multifactorial including hormonal effects on lower oesophageal sphincter function, and mechanical factors.[1]

This is a part of article Gastro-oesophageal Reflux During Pregnancy: Treat With Care Taken from "Sucralfate Carafate" Information Blog

BBC SPORT | Rugby League | Super League | Saints finish lights up Super League

By Dave Woods BBC Sport

Go on, pinch yourself Warrington fans, but you won't wake from the nightmare.

Dave Woods' team of the week

It's still impossible to understand how St Helens turned certain defeat into one of the unlikeliest wins in Super League.

The Wolves, who played terrifically well for the most part, led 16-4 with barely six minutes left.

Warrington 16-18 St Helens

Then in a thrilling finale, Saints managed to squeak it, scoring three tries, including one with the very last play of the game.

It's a St Helens trademark - and they managed it without Long, Sculthorpe and Hooper.

Warrington were within seconds of seeing their season take off. But now they have to rebuild confidence again ahead of Leeds away next week.

Hull were powerfully impressive against a very well-organised Salford.

Salford 12-22 Hull

Paul Cooke put in a superb individual show - the two passes he produced to send over for Gareth Raynor and Kirk Yeaman would have had Hull fans of a certain age reminiscing about Steve "Knocker" Norton.

Salford are good though - top six is not beyond them.

Bradford's win over London Broncos can be filed in the "that's more like it" column.

Bradford 48-22 London

Apart from the opening 20 minute spell when London competed, the Bulls bossed the game looking back to their confident, powerful best.

Still, London's most important win of the week came off the field in the Super League boardrooms.

Their home games remain a priority and next week's match versus Wigan is of enormous significance.

Another defeat for Leigh, but give them credit for a battling approach to the game against Wakefield at the Atlantic Solutions Stadium.

Wakefield 38-26 Leigh

The freshly poured glass of champagne that was Trinity's initial form seems to have turned into half a carafe of cheap house wine.

They need to rediscover that early bubbliness they had.

And they certainly deserve better than a crowd of not much more than 4,000.

Widnes have now completed the opening month from hell, and the signs are they can kick on from here.

Widnes 20-32 Wigan

Two points from the first four fixtures against St Helens, Bradford, Leeds and Wigan could have been four points had it not been for a late fight-back by the Warriors at the Halton Stadium.

Widnes held the lead with around 20 minutes remaining, but Wigan had the stronger finish.

And what are we to make of Huddersfield?

Alright it was Leeds who trounced them at the Galpharm and Leeds are trouncing everyone at the moment.

But it's the third successive week that the Giants have got off to a dozy start, and this time they couldn't muster a fightback.

Huddersfield 10-54 Leeds

Last year the Giants were flying at this stage, this year they have only a win at Leigh from their first four weeks.

It's form that has to change quickly as the Super League table begins to take shape.


This is a part of article BBC SPORT | Rugby League | Super League | Saints finish lights up Super League Taken from "Sucralfate Carafate" Information Blog

FDA Safety Changes: Mevacor, Ortho Evra, Cipro

FDA Safety Changes: Mevacor, Ortho Evra, Cipro  CME/CE

News Author: Yael Waknine
CME Author: Yael Waknine
DisclosuresRelease Date: March 15, 2006; Valid for credit through March 15, 2007

March 15, 2006 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of the need for reduced doses of lovastatin to reduce the associated risk for myopathy in patients receiving cyclosporine or danazol; the potential for an increased risk for estrogen-related adverse events in patients using a norelgestromin/ethinyl estradiol transdermal system; and contraindication of ciprofloxacin extended-release tablets in tizanidine-treated patients due to a risk for increased hypotensive and sedative effects.Lovastatin (Mevacor) Plus Cyclosporine or Danazol Linked to Increased Risk for Myopathy

On November 4, 2005, the FDA approved safety labeling revisions for lovastatin tablets (Mevacor, made by Merck & Co, Inc) to warn of drug interactions that may increase the risk for adverse events associated with their use.

As with other 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, lovastatin is linked to a dose-related risk for myopathy that presents as muscle pain, tenderness, or weakness, with elevated creatine kinase levels greater than 10 times the upper limit of normal. Myopathy may also take the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have been reported.

Because lovastatin is a substrate for the cytochrome P-450 isoform 3A4 (CYP3A4) enzyme, concomitant administration of potent CYP3A4 inhibitors may result in elevated HMG-CoA plasma levels and an increased risk for these adverse events.

Although the mechanism is not fully understood, cyclosporine has been shown to increase the area under the curve of HMG-CoA inhibitors, including lovastatin. According to the FDA, these findings are thought to be due in part to CYP3A4 inhibition.

Concomitant use of danazol may also increase the risk for myopathy and/or rhabdomyolysis, particularly at higher doses of lovastatin.

Lovastatin should therefore be used with caution in patients receiving cyclosporine or danazol and initiated at a reduced dose of 10 mg/day and uptitrated as needed to doses not exceeding 20 mg/day. Therapy should be discontinued immediately if myopathy is diagnosed or suspected.

Lovastatin tablets are indicated for the primary prevention of coronary heart disease, to slow the progression of coronary atherosclerosis in patients with coronary heart disease, and to reduce the risk for atherosclerotic vascular disease in patients with dyslipidemia.Norelgestromin/Ethinyl Estradiol Patch (Ortho Evra) May Increase Risk for Estrogen-Related Adverse Events

On November 10, 2005, the FDA approved safety labeling revisions for a norelgestromin/ethinyl estradiol transdermal system (Ortho Evra, made by Johnson and Johnson Pharmaceutical Research and Development, LLC) to warn that its use may be linked to an increased risk for estrogen-related adverse events, relative to oral contraceptives containing 35-µg ethinyl estradiol.

According to the FDA, the data from pharmacokinetic studies has revealed estradiol area-under-the-curve and steady-state concentrations to be approximately 60% higher in women using the patch compared with oral contraceptives. In contrast, peak concentrations are approximately 25% lower in women using the transdermal system.

The FDA notes that because intersubject variability is higher among women using the patch than those receiving combination oral contraceptives, the potential for an increased risk for serious estrogen-related adverse events based on the differing pharmacokinetic profile remains unclear.

In addition, limited epidemiologic data exist to determine whether the safety of transdermal delivery differs from that of the oral route in patients using combination hormonal contraceptives.

The norelgestromin/ethinyl estradiol patch is indicated for contraceptive use in women.Ciprofloxacin Extended-Release Tablets (Cipro) Contraindicated in Tizanidine-Treated Patients

On November 9, 2005, the FDA approved safety labeling revisions for ciprofloxacin extended-release tablets (Cipro, made by Bayer Pharmaceuticals Corp) to warn against their use in patients receiving tizanidine HCl.

Ciprofloxacin is also contraindicated in patients with a history of hypersensitivity to the drug, other quinolones antibiotics, or tablet excipients, including crospovidone, hypromellose, magnesium stearate, polyethylene glycol, silica colloidal anhydrous, succinic acid, and titanium dioxide.

Because ciprofloxacin is an inhibitor of cytochrome P450 1A2 (CYP1A2)-mediated metabolism, coadministration with CYP1A2-metabolized tizanidine results in increased tizanidine plasma concentrations that could lead to clinically significant adverse events.

In a pharmacokinetic study, systemic exposure of tizanidine (4-mg single dose) was significantly increased (Cmax, 7-fold; area under the curve, 10-fold) when the drug was given concurrently with ciprofloxacin (500 mg twice daily for 3 days). As a result, the hypotensive and sedative effects of tizanidine were also potentiated.

Extended-release ciprofloxacin tablets are indicated for the treatment of urinary tract infections, including acute uncomplicated pyelonephritis, caused by susceptible strains of designated microorganisms. The FDA notes that the safety and efficacy of the product for treating other infections has not been determined.

Tizanidine (Zanaflex, made by Elan Pharmaceuticals, Inc) is a short-acting drug indicated for the management of spasticitiy.

http://www.fda.gov/medwatch/safety/2005/nov05.htm

Pearls for Practice

Because concurrent use of cyclosporine and danazol may increase the risk for myopathy and/or rhabdomyolosis associated with lovastatin, it should be initiated at a reduced dose of 10 mg/day and uptitrated to doses not exceeding 20 mg/day in patients receiving combination therapy. Lovastatin should be immediately discontinued if myopathy is diagnosed or suspected.Use of a norelgestromin/ethinyl estradiol transdermal system yields about 60% higher steady-state and 25% lower peak concentrations of estradiol compared with oral combination contraceptives. The potential for increased adverse events related to elevated estrogen exposure remains unclear.Ciprofloxacin intravenous infusion is contraindicated in patients receiving tizanidine because of the risk for adverse events caused by elevated tizanidine levels.

Medscape Medical News 2006. © 2006 Medscape

Legal Disclaimer The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
This is a part of article FDA Safety Changes: Mevacor, Ortho Evra, Cipro Taken from "Best Antibiotic: Cipro Ciprofloxacin" Information Blog

Last report: most of visitors prefer xxxfreemovies videos, not xxxfreemovies pics.

Last report: most of visitors prefer xxxfreemovies videos, not amature vids pics.